Dr. Robert Zweigerdt
Phone: +49 511 532-5023
Leibniz Research Laboratories for
Biotechnology and Artificial Organs (LEBAO)
Department of Cardiothoracic, Transplantation and Vascular Surgery (HTTG)
Head of Department
Prof. Dr. Axel Haverich (clinical director)
Prof. Dr. Ulrich Martin (research director)
Location of Workgroup
Medizinische Hochschule Hannover
Mass Production of Pluripotent Stem Cells and Derivatives
We aim to
- Establish human pluripotent stem cell (hPSC) culture (including hiPSCs and hESCs) in clinical scale and grade.
- Establish efficient cardiomyogenic differentiation of hPSCs and provide. cardiomyocytes for tissue engineering and heart repair in pre-clinical animal model.
- Perform process development for hPSC production and differentiation in controlled bioreactor.
- Achieve in vitro modeling of congenital cardiomyopathie.
- Achieve process up-scaling to 1 Liter scale in stirred bioreactors.
Our research resulted in recent milestone papers on the defined, single cell inoculated cultivation of human pluripotent stem cells (hPSC, including hESCs and hiPSCs) as “cells only” aggregates in suspension culture, independent of micro carriers or other extracellular matrices. This technique, for the first time, enables straightforward up-scaling of hPSC culture in, fully controllable stirred-tank bioreactors providing the required “raw material” for the mass production of any differentiated human PSC-derived progenies. Independent research allowed the generation of pure human hPSC-derived cardiomyocytes (CMs) in chemically defined, clinically compliant culture media in suspension culture. We are currently working on combining the hPSC suspension culture process with our CMs differentiation protocol in controlled bioreactors to develop clinically relevant conditions for CMs production. Cells will be provided “on-demand” in frame of REBIRTH-2 collaborative projects, particularly for cardiac tissue engineering and in vitro modelling of cardiomyopathies.
- Robust hPSC expansion and maintenance of pluripotency when cultured in suspension as “cell only” aggregates in 100 ml scale stirred bioreactors in defined media
- Efficient cardiomyogenic differentiation of hPSCs in stirred bioreactors achieving 80-90% cardiomyocyte purity in chemically defined media
- Proteomics of hPSC culture platforms; F. Büttner, REBIRTH-Unit Stem Cell Glycomics and Proteomics, MHH
- Single cell suspension culture; S. Cowley, Oxford University, StemBANCC
- In vitro modeling of Hypertrophic Cardiomyopathy; T. Kraft, B. Brenner, U Martin, REBIRTH-Unit Large Animal Models, MHH
- Electrophysiological assessment of Cardiomyocytes; P. Sasse, B. Fleischmann, Life & Brain Center, Bonn
- Cardiac Tissue Engineering & Animal Models; I. Gruh, A. Haverich, REBIRTH-Unit Myocardial Tissue Engineering, MHH
- Tomography-based monitoring of hPSC aggregates in 3D-culture; H. Meyer, REBIRTH-Unit Laser Manipulation and Cellular Engineering, Laser Zentrum Hannover
- Chemical compounds and recombinant factors for culture media development; T. Scheper, REBIRTH-Unit Production and Purification of Recombinant Polymers, A. Kirschning, G. Dräger, REBIRTH-Unit Functional Polymers and Regenerative Agents, Leibniz Universität Hannover
- StemBANCC: Large-scale, 5 year academic-industry partnership. Aims: hiPSC lines for in vitro modeling of chronic diseases and drug testing.
Established industrial collaborations on process development & reactor technology with:
- STEMCELL Technologies (Vancouver, Canada)
- DASGIP / Eppendorf (Jühlich / Hamburg, Germany)
Equipment and Service Facilities
[Please find the publications of this workgroup here]
|Zweigerdt, Robert Dr.||Zweigerdt.Robert(at)mh-hannover.de|
|Olmer, Ruth Dr.||Olmer.Ruth(at)mh-hannover.de|
|Schwanke, Kristin Dr.||Schwanke.Kristin(at)mh-hannover.de|
|Robles Diaz, Diana||r.diaz.diana(at)gmail.com|